148 related articles for article (PubMed ID: 30410635)
1. Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database.
Liu PP; Xia Y; Bi XW; Wang Y; Sun P; Yang H; Li ZM; Jiang WQ
Dis Markers; 2018; 2018():7473935. PubMed ID: 30410635
[TBL] [Abstract][Full Text] [Related]
2. Role of radiation therapy in primary breast diffuse large B-cell lymphoma in the Rituximab era: a SEER database analysis.
Liu PP; Wang KF; Jin JT; Bi XW; Sun P; Wang Y; Yang H; Li ZM; Jiang WQ; Xia Y
Cancer Med; 2018 May; 7(5):1845-1851. PubMed ID: 29624913
[TBL] [Abstract][Full Text] [Related]
3. Addition of Rituximab to Chemotherapy Reduced the Rate of Surgery for Gastric-DLBCL Without Increasing Early Mortality.
Prouet P; Giri S; Wiedower E; Fintel A; Yaghmour G; Lamb EP; Deneve J; Fleming M; Dickson P; Chandler JC; Martin MG
Anticancer Res; 2017 Feb; 37(2):813-817. PubMed ID: 28179335
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of primary gastric diffuse large B cell lymphoma in the rituximab era: a multicenter study of 95 patients in Japan.
Tanaka T; Shimada K; Yamamoto K; Hirooka Y; Niwa Y; Sugiura I; Kitamura K; Kosugi H; Kinoshita T; Goto H; Nakamura S
Ann Hematol; 2012 Mar; 91(3):383-90. PubMed ID: 21822617
[TBL] [Abstract][Full Text] [Related]
5. Survival in advanced diffuse large B-cell lymphoma in pre- and post-rituximab Eras in the United States.
Shah BK; Bista A; Shafii B
Anticancer Res; 2014 Sep; 34(9):5117-20. PubMed ID: 25202101
[TBL] [Abstract][Full Text] [Related]
6. Multi-Database Description of Primary Splenic Diffuse Large B-Cell Lymphoma.
Byrd KP; Vontela NR; McCullar B; Martin MG
Anticancer Res; 2017 Dec; 37(12):6839-6843. PubMed ID: 29187463
[TBL] [Abstract][Full Text] [Related]
7. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
8. Recent survival trends in diffuse large B-cell lymphoma--Have we made any progress beyond rituximab?
Epperla N; Vaughn JL; Othus M; Hallack A; Costa LJ
Cancer Med; 2020 Aug; 9(15):5519-5525. PubMed ID: 32558356
[TBL] [Abstract][Full Text] [Related]
9. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Winer ES; Olszewski AJ
Am J Hematol; 2014 Mar; 89(3):310-4. PubMed ID: 24273125
[TBL] [Abstract][Full Text] [Related]
10. Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis.
Morgensztern D; Walker GR; Koniaris LG; Lossos IS
Leuk Lymphoma; 2011 Feb; 52(2):194-204. PubMed ID: 21281235
[TBL] [Abstract][Full Text] [Related]
11. A comparative population-based analysis of sinonasal diffuse large B-cell and extranodal NK/T-cell lymphomas.
Dubal PM; Dutta R; Vazquez A; Patel TD; Baredes S; Eloy JA
Laryngoscope; 2015 May; 125(5):1077-83. PubMed ID: 25546466
[TBL] [Abstract][Full Text] [Related]
12. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
13. Primary testicular diffuse large B-cell lymphoma: a population-based study on the incidence, natural history, and survival comparison with primary nodal counterpart before and after the introduction of rituximab.
Gundrum JD; Mathiason MA; Moore DB; Go RS
J Clin Oncol; 2009 Nov; 27(31):5227-32. PubMed ID: 19770371
[TBL] [Abstract][Full Text] [Related]
14. IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era.
Chen X; Zang Y; Li D; Guo J; Wang Y; Lin Y; Wei Z
Medicine (Baltimore); 2020 May; 99(21):e19883. PubMed ID: 32481253
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in treatment of primary gastric diffuse large B-cell lymphoma.
Zhang J; Li G; Yang H; Liu X; Cao J
Leuk Lymphoma; 2012 Nov; 53(11):2175-81. PubMed ID: 22462613
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
17. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
18. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
19. Primary Gastric Diffuse Large B-Cell Lymphoma: Prognostic Factors in the Immuno-Oncology Therapeutics Era.
Bai Z; Li Z; Guan T; Wang L; Wang J; Wu S; Su L
Turk J Haematol; 2020 Aug; 37(3):193-202. PubMed ID: 32160735
[TBL] [Abstract][Full Text] [Related]
20. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
